Format

Send to

Choose Destination
See comment in PubMed Commons below
Neuropsychopharmacology. 2015 Jan;40(2):259-67. doi: 10.1038/npp.2014.261. Epub 2014 Sep 26.

Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Author information

1
Yale University School of Medicine, New Haven, CT, USA.
2
Stanford University School of Medicine, Stanford, CA, USA.

Abstract

Large 'real world' studies demonstrating the limited effectiveness and slow onset of clinical response associated with our existing antidepressant medications has highlighted the need for the development of new therapeutic strategies for major depression and other mood disorders. Yet, despite intense research efforts, the field has had little success in developing antidepressant treatments with fundamentally novel mechanisms of action over the past six decades, leaving the field wary and skeptical about any new developments. However, a series of relatively small proof-of-concept studies conducted over the last 15 years has gradually gained great interest by providing strong evidence that a unique, rapid onset of sustained, but still temporally limited, antidepressant effects can be achieved with a single administration of ketamine. We are now left with several questions regarding the true clinical meaningfulness of the findings and the mechanisms underlying the antidepressant action. In this Circumspectives piece, Dr Sanacora and Dr Schatzberg share their opinions on these issues and discuss paths to move the field forward.

Comment in

PMID:
25257213
PMCID:
PMC4443967
DOI:
10.1038/npp.2014.261
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center